Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty
Issued Date
2024-08-01
Resource Type
ISSN
12797707
eISSN
17604788
Scopus ID
2-s2.0-85198727561
Journal Title
Journal of Nutrition, Health and Aging
Volume
28
Issue
8
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Nutrition, Health and Aging Vol.28 No.8 (2024)
Suggested Citation
Niyomnaitham S., Chokephaibulkit K., Pheerapanyawaranun C., Toh Z.Q., Licciardi P.V., Satayasanskul A., Jansarikit L., Assantachai P. Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty. Journal of Nutrition, Health and Aging Vol.28 No.8 (2024). doi:10.1016/j.jnha.2024.100315 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/99766
Title
Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty
Corresponding Author(s)
Other Contributor(s)
Abstract
Objectives: Impact of frailty towards immunogenicity and reactogenicity of BNT162b2 boosters administered via intramuscular or intradermal routes in a Thai geriatric population Design: Prospective, randomized, open-labeled. Setting: Siriraj Hospital, Thailand. Participants: Geriatric adults aged ≥65 years. Intervention: 10 μg intradermal or 30 μg intramuscular BNT162b2 (Pfizer-BioNTech). Measurements: Anti-SARS-CoV-2 receptor binding domain IgG, neutralizing antibodies (NAb), and interferon-gamma producing cells against Wuhan and Omicron BA.4/5. Analyses were stratified based on participants’ Clinical Frailty Scale. Results: A total of 139 participants were included in the analysis. Two-four weeks post-booster administration, NAb titers against Wuhan but not Omicron BA.4/5 were significantly lower among frail participants than non-frail participants who received intramuscular administration. Spike-specific T cell responses were similar for frail and non-frail participants, regardless of administration route. Frail participants who received intradermal BNT162b2 had fewer local adverse events (AEs), but higher systemic AEs than non-frail participants. Conclusion: Similar immune responses across vaccine routes warrants further evaluation of intradermal BNT162b2 in frail geriatric populations. Frail participants may be more sensitive to reporting systemic AEs. Registration of clinical trials: The parent study was registered under the Thai Clinical Trials Registry (TCTR20220112002).